NCT00775957

Brief Summary

A study to determine the accuracy of FLT-PET in quantifying tumor cell proliferation at the initial staging of patients with Non-Hodgkin's Lymphoma in comparison wit the "gold standard" FDG-PET.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
35

participants targeted

Target at P25-P50 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2008

Completed
16 days until next milestone

First Submitted

Initial submission to the registry

October 17, 2008

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 20, 2008

Completed
Last Updated

September 28, 2010

Status Verified

September 1, 2010

First QC Date

October 17, 2008

Last Update Submit

September 27, 2010

Conditions

Non-Hodgkin's Lymphoma

Outcome Measures

Primary Outcomes (1)

  • Staging and ReStaging scans

    after hematopoetic recovery

Study Arms (2)

1

FLT-PET Scan

Procedure: FLT-PET scan

2

FDG-PET Scan

Procedure: FDG-PET scan

Interventions

FLT-PET scanPROCEDURE

imaging scan

1
FDG-PET scanPROCEDURE

imaging scan

2

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Subjects diagnosed with lymphoma and are about to start treatment with chemotherapy

You may qualify if:

  • years or older
  • Women must not be pregnant or breast feeding
  • Histologic diagnosis of non-Hodgkin's lymphoma (any stage)
  • Must undergo treatment with chemotherapy and/or radiotherapy

You may not qualify if:

  • May not have received previous therapy with radiopharmaceuticals
  • May not have received prior therapy with cytotoxic chemotherapy and/or monoclonal antibodies

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States

Location

MeSH Terms

Conditions

Lymphoma, Non-Hodgkin

Condition Hierarchy (Ancestors)

LymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

October 17, 2008

First Posted

October 20, 2008

Study Start

October 1, 2008

Last Updated

September 28, 2010

Record last verified: 2010-09

Locations

US(1)